NCIt definition : A fully human, glycoengineered monoclonal antibody targeting B7-H4 (V-set domain-containing
T-cell activation inhibitor 1; VTCN1; B7x; B7S1) with potential antineoplastic and
immune checkpoint inhibitory activities. Upon intravenous administration, alsevalimab
binds to B7-H4 on the surface of tumor cells, thereby preventing B7-H4 binding to
T-cells and abrogating the B7-H4-mediated negative regulation of T-cell activation.
This increases a cytotoxic T-lymphocyte (CTL)-mediated immune response against B7-H4-expressing
tumor cells. In addition, the afucosylated Fc region of the anti-B7-H4 monoclonal
antibody FPA150 enhances its binding affinity for human FcgammaRIIIa receptors (CD16)
on natural killer (NK) cells, resulting in enhanced antibody-dependent cellular cytotoxicity
(ADCC) against B7-H4-expressing tumor cells. B7-H4, a member of the B7 family of immune
modulators, is upregulated in a variety of tumor cell types and negatively regulates
T-cell immune responses.;
UNII : U8LYN0Y118;
CAS number : 2254029-91-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2254029-91-7
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)